SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO

SEB Asset Management AB acquired a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the first quarter, HoldingsChannel reports. The fund acquired 163,860 shares of the company’s stock, valued at approximately $3,203,000.

Other hedge funds also recently made changes to their positions in the company. SR One Capital Management LP increased its holdings in Zenas BioPharma by 2.6% in the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after acquiring an additional 126,315 shares in the last quarter. NEA Management Company LLC lifted its holdings in Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma in the fourth quarter worth approximately $38,402,000.

Insiders Place Their Bets

In related news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired 120,000 shares of company stock worth $2,080,000 over the last three months. Company insiders own 22.00% of the company’s stock.

Analysts Set New Price Targets

ZBIO has been the subject of a number of analyst reports. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zenas BioPharma presently has an average rating of “Moderate Buy” and an average target price of $44.29.

Zenas BioPharma Trading Down 1.6%

ZBIO stock opened at $30.99 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. Zenas BioPharma, Inc. has a 1-year low of $13.50 and a 1-year high of $44.60. The business has a 50 day simple moving average of $22.73 and a two-hundred day simple moving average of $22.01. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -3.66 and a beta of -0.96.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter in the prior year, the firm posted ($0.80) EPS. Research analysts anticipate that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.